A New Approach to Tumor Cancer with a Novel Imaging Profile for White matter abnormalities including Leukodystrophies: Sensing the Human Brain

Abstract

Neuromolecular Imaging (NMI) for white matter detection, distinct from that of gray matter is an inventive art. (1) This imaging technique demonstrates, for the first time, a LIVE and continuous videotracking nanotechnology for distinguishing white matter from gray matter in the brain of epilepsy patients, online, in real time and for long periods of time. NMI is known to perform with unrivaled temporal and spatial operational reliability and reproducibility Thus, a nanotechnology for white matter disorders, for example, leukodystrophies, is published for the first time. The purpose of this paper is to present a critical distinction for white versus gray matter in hippocampal and neocortical resected tissue derived from mesial and neocortical temporal lobe epilepsy patients en bloc during intraoperative surgery; the patients present as medically refractory to classical pharmacotherapeutics. The tiny carbon-based lipid polymeric sensor, the BRODERICK PROBE^® readily sees white matter in contrast to gray matter in brain neuroanatomic substrates as it continually senses the glia or the neuron, white or gray matter, respectively, with distinct clarity via electroactive signal processing. The difference between white and gray matter is striking as the videotrace slides smoothly from the white to the gray milieu. Thus, a primary in vivo white matter nanotechnology is presented to advance diagnosis and therapy for white and gray matter abnormalities in the brain and spinal cord.